Sectors

Based in Shanghai, China, Zou has worked her way up from investment manager since joining LAV in May 2015.

Ensoma has emerged with $70m in series A financing to advance research from Fred Hutchinson and University of Washington.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.

Coupang is reportedly looking to achieve a $50bn market cap following a planned listing that would offer an exit to both SoftBank and its Vision Fund.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.

Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.

Allianz will receive a minority stake in the financial services technology provider after agreeing to invest $42.2m in funding.

KDDI Open Innovation Fund has thrown its weight behind Swift Navigation, a global positioning technology developer already backed by Qualcomm Ventures.

Eli Lilly has led a series C round for the diabetes treatment developer, which plans to complete preclinical testing of its lead therapy.